Pathogenetic rationale for prostanoids and role of inhaled iloprost in the treatment of pulmonary hypertension

Close metadata

Recommended articles:

Pulmonary arterial hypertension in disorders of porto-caval hemodynamics. The role of ultrasound diagnostics. Russian Cardiology Bulletin. 2025;(1):90-98

Pulmonary hypertension is a severe cardiovascular disease followed by extremely poor prognosis without treatment. To date, prostanoids in all their forms are effective for pulmonary hypertension, but their use is significantly limited due to peculiarities of delivery of active molecules and side effects caused by unique characteristics of biochemical reactions. This review highlights the possibilities and limitations of these drugs, in particular inhaled iloprost. It is the only drug approved for pulmonary hypertension in our country. We also discuss the prospects for further use of prostanoids and overcoming existing limitations.

Keywords:

pulmonary hypertension

prostanoids

iloprost

right ventricular heart failure

Authors:

Tkacheva A.A.

Chazov National Medical Research Center of Cardiology

Valieva Z.S.

Chazov National Medical Research Center of Cardiology

Martynyuk T.V.

National Medical Research Center of Cardiology

Scopus AuthorID: 6602715051
ORCID: 0000-0002-9022-8097

Received:

27.10.2022

Accepted:

05.12.2022

List of references:

Chazova IE, Martynyuk TV, Valieva ZS. Azizov VA, Barbarash OL, Veselova TN, Galyavich AS, Gorbachevskii SV, Zelveyan PA, Lazareva IV, Mukarov MA, Nakonechnikov SN, Saidova MA, Sarybaev ASh, Stukalova OV, Shalaev SV, Shmal’ts AA. Eurasian clinical guidelines for the diagnosis and treatment of pulmonary hypertension. Eurasian heart journal. 2020;1:78-122. (In Russ.). https://doi.org/10.38109/2225-1685-2020-1-78-122
Lang IM, Gaine SP. Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. The European Respiratory Review. 2015;24(138):630-641. https://doi.org/10.1183/16000617.0067-2015
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43(38):3618-3731. https://doi.org/10.1093/eurheartj/ehac237
Mitchell JA, Ahmetaj-Shala B, Kirkby NS, Wright WR, Mackenzie LS, Reed DM, Mohamed N. Role of prostacyclin in pulmonary hypertension, Global Cardiology Science and Practice. 2015;2014(4):53. https://doi.org/10.5339/gcsp.2014.53
Avdeev SN, Barbarash OL, Bautin AE, Volkov AV, Veselova TN, Galyavich AS, Goncharova NS, Gorbachevsky SV, Danilov NM, Eremenko AA, Martynyuk TV, Moiseeva OM, Saidova MA, Sergienko VB, Simakova MA, Stukalova OV, Chazova IE, Chernyavsky AM, Shalaev SV, Shmalts AA, Tsareva NA. 2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian Journal of Cardiology. 2021;26(12):4683. (In Russ.). https://doi.org/10.15829/1560-4071-2021-4683
Smith WL. The eicosanoids and their biochemical mechanisms of action. Biochemical Journal. 1989;259(2):315-324. https://doi.org/10.1042/bj2590315
Warner TD, Mitchell JA. Nonsteroidal antiinflammatory drugs inhibiting prostanoid efflux: as easy as ABC? Proceedings of the National Academy of Sciences. 2003;100(16):9108-9110. https://doi.org/10.1073/pnas.1733826100
Gubrij IB, Martin SR, Pangle AK, Kurten R, Johnson LG. Attenuation of monocrotaline-induced pulmonary hypertension by luminal adeno-associated virus serotype 9 gene transfer of prostacyclin synthase. Human Gene Therapy. 2014;25(6):498-505. https://doi.org/10.1089/hum.2013.187
Geraci MW, Gao B, Shepherd DC, Moore MD, Westcott JY, Fagan KA, Alger LA, Tuder RM, Voelkel NF. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. Journal of Clinical Investigation. 1999;103(11):1509-1515. https://doi.org/10.1172/JCI5911
Zhou L, Chen Z, Vanderslice P, So SP, Ruan KH, Willerson JT, Dixon RA. Endothelial-like progenitor cells engineered to produce prostacyclin rescue monocrotaline-induced pulmonary arterial hypertension and provide right ventricle benefits. Circulation. 2013;128(9):982-994. https://doi.org/10.1161/CIRCULATIONAHA.113.003139
Harrington LS, Moreno L, Reed A, Wort SJ, Desvergne B, Garland C, Zhao L, Mitchell JA. The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension. PLoS One. 2010;5(3):e9526. https://doi.org/10.1371/journal.pone.0009526
Farber HW, Gin-Sing W. Practical considerations for therapies targeting the prostacyclin pathway. The European Respiratory Review. 2016;25(142):418-430. https://doi.org/10.1183/16000617.0083-2016
Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, Diehl JH, Crow J, Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Annals of Internal Medicine. 1990;112(7):485-491. https://doi.org/10.7326/0003-4819-112-7-485
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD, Shortino D, Crow JW; Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The New England Journal of Medicine. 1996;334(5):296-301. https://doi.org/10.1056/NEJM199602013340504
Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jöbsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA Jr. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Annals of Internal Medicine. 2000;132(6):425-434. https://doi.org/10.7326/0003-4819-132-6-200003210-00002
Badesch DB, McGoon MD, Barst RJ, Tapson VF, Rubin LJ, Wigley FM, Kral KM, Raphiou IH, Crater GD. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. Journal of Rheumatology. 2009;36(10):2244-2249. https://doi.org/10.3899/jrheum.081277
Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, Rubin LJ, Horn EM, Manes A, Simonneau G.. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. European Respiratory Journal. 2004;24(3):353-359. https://doi.org/10.1183/09031936.04.00028404
Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB; PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Annals of Internal Medicine. 2008;149(8):521-530. https://doi.org/10.7326/0003-4819-149-8-200810210-00004
GlaxoSmithKline. Flolan [prescribing information]. Research Triangle Park, GlaxoSmithKline, 2015.
Vachiéry JL, Hill N, Zwicke D, Barst R, Blackburn S, Naeije R. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest. 2002;121(5):1561-1565. https://doi.org/10.1378/chest.121.5.1561
United Therapeutics Corp. Orenitram [prescribing information]. Research Triangle Park, United Therapeutics Corp., 2014.
United Therapeutics Corp. Tyvaso [prescribing information]. Research Triangle Park, United Therapeutics Corp., 2014.
Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European Heart Journal. 2016;37(1):67-119. https://doi.org/10.1093/eurheartj/ehv317
Sadushi-Koliçi R, Skoro-Sajer N, Zimmer D, Bonderman D, Schemper M, Klepetko W, Glatz J, Jakowitsch J, Lang IM. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. The Journal of Heart and Lung Transplantation. 2012;31(7):735-743. https://doi.org/10.1016/j.healun.2012.02.025
Galiè N, Humbert M, Vachiéry JL, Vizza CD, Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M, Naeije R, Hoeper M, Chaouat A, Morand S, Besse B, Simonneau G; Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. JACC: Journal of the American College of Cardiology. 2002;39(9):1496-1502. https://doi.org/10.1016/s0735-1097(02)01786-2
Martynyuk TV. Legochnaya gipertenziya: diagnostika i lechenie. M.: MIA; 2018. (In Russ.).
Actelion Pharmaceuticals. Ventavis [prescribing information]. San Francisco, Actelion Pharmaceuticals US, Inc, 2013.
Bayer. Ilomedin [prescribing information]. Auckland, Bayer, 2012.
Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, F.R.C.P., Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W. Inhaled iloprost for severe pulmonary hypertension. The New England Journal of Medicine. 2002;347(5):322-329. https://doi.org/10.1056/NEJMoa020204
Opitz CF, Wensel R, Winkler J, Halank M, Bruch L, Kleber FX, Höffken G, Anker SD, Negassa A, Felix SB, Hetzer R, Ewert R. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. European Heart Journal. 2005;26(18):1895-1902. https://doi.org/10.1093/eurheartj/ehi283
Olschewski H, Hoeper MM, Behr J, Ewert R, Meyer A, Borst MM, Winkler J, Pfeifer M, Wilkens H, Ghofrani HA, Nikkho S, Seeger W.. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respiratory Medicine. 2010;104(5):731-740. https://doi.org/10.1016/j.rmed.2010.01.008
McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine. 2006;174(11):1257-1263. https://doi.org/10.1164/rccm.200603-358OC
Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K, Frantsve-Hawley J, Kawut SM, Ryan JJ, Rosenzweig EB, Sederstrom N, Steen VD, Badesch DB. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. Chest. 2019;155(3):565-586. https://doi.org/10.1016/j.chest.2018.11.030
Martynyuk TV. Evaluation of compliance of pulmonary hypertension patients to the treatment with inhaled iloprost (Ventavis): results of prospective, multicenter, non-interventional IVENT study. Systemic Hypertension. 2019;16(2):12-27. (In Russ.). https://doi.org/10.26442/2075082X.2019.2.190352
Sitbon O, Jaïs X, Savale L, Cottin V, Bergot E, Macari EA, Bouvaist H, Dauphin C, Picard F, Bulifon S, Montani D, Humbert M, Simonneau G. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. European Respiratory Journal. 2014;43(6):1691-1697. https://doi.org/10.1183/09031936.00116313
McGoon MD. Upfront triple therapy for pulmonary arterial hypertension: is three a crowd or critical mass? European Respiratory Journal. 2014;43(6):1556-1559. https://doi.org/10.1183/09031936.00039314

Close metadata